miRecule, Inc. Alternatives & Competitors
12 companies similar to miRecule, Inc. — RNA Therapeutics
Companies similar to miRecule, Inc.
Dyne Therapeutics
Advancing life-transforming therapies for serious muscle diseases
FREZENT Biological
Preventing cancer recurrence
Elixirgen Therapeutics, Inc.
Reimagine the Power of RNA
AIRNA
The next generation of RNA editing therapeutics
Rival Readout
Competing with miRecule, Inc.? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Onchilles Pharma
Developing drug candidates that have the potential to be broadly effective against a wide...
Rgenta Therapeutics Inc.
We unlock the therapeutic potentials of highly disease-relevant targets undruggable by sma...
Rakuten Medical
Rakuten Medical, Inc. is a global biotechnology company in pursuit of conquering cancer.
Kynexis
Kynexis is advancing the first potential precision medicine for the treatment of CIAS.
Elevation Oncology
We are focused on discovering and developing selective cancer therapies to treat patients...
NextPoint Therapeutics, Inc.
Launching a new world of precision therapeutics through its leading scientific work on th...
Crossbow Therapeutics, Inc
Established antibody engineering to target the untapped universe of intracellular cancer t...
Systems Oncology
Deeper Insights, Multimodal Drugs - We translate genomic intelligence into multi-targeting...
About miRecule, Inc.
miRecule, Inc., a promising player in the RNA Therapeutics domain, is pioneering first-in-class RNA-based therapies, focusing on conditions such as Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Established in 2016, this United States-based startup operates within the Bi...
Development of RNA therapies for cancer and muscular dystrophy, Creation of antibody RNA conjugate therapeutics, Utilization of genomic and outcome data for therapeutic development, Expansion of strategic collaborations (e.g., with Sanofi)
Patients with cancer, Patients with muscular dystrophy, Patients suffering from neuromuscular diseases, Healthcare providers specializing in rare genetic diseases
RNA Therapeutics, First-in-Class Therapies, Head & Neck Squamous Cell Carcinoma, Facioscapulohumeral Muscular Dystrophy, Genomic Patient Data, Tailored Therapeutics, DREAmiR™ Platform, Genetic Alteration Targeting, RNA Therapeutics Development, Antibody RNA Conjugate (ARC), Genomic Medicine, Cancer Therapies, Muscular Dystrophy Therapies, Precision Medicine
B2B, B2D, B2B2B
Licensing, Performance Based, Product Sales
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around miRecule, Inc.: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at miRecule, Inc. on 11 Mar 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.